Xintela AB (publ) recently announced that they have initiated the third and last dose level in the phase I/IIa study with the stem cell product XSTEM in patients with knee osteoarthritis. The company's goal is to present safety data from all dose levels and early efficacy results in 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.281 SEK | +2.55% | +6.04% | +3.69% |
Feb. 28 | Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Feb. 20 | Xintela Names New Chief Scientific Officer | MT |
1st Jan change | Capi. | |
---|---|---|
+3.69% | 14.53M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- XINT Stock
- News Xintela AB
- Xintela AB Initiates Last Dose Level in Knee Osteoarthritis Study